<DOC>
	<DOCNO>NCT02103738</DOCNO>
	<brief_summary>This observational study evaluate compare two Ranibizumab treatment regimen ( Standard care ) patient neovascular ( wet ) age-related macular degeneration ( wAMD ) aim achieve maintain maximum visual function benefit . The result use generate recommendation time treatment administration patient neovascular ( wet ) age-related macular degeneration ( wAMD ) . In context , study use anatomical imaging ( example , optical coherence tomography [ OCT ] ) evaluate wAMD disease activity impact recurrence disease instability decision make treatment decision algorithm .</brief_summary>
	<brief_title>Canadian Treat Extend Analysis Trial With Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Infomed consent , Male Female , 50 year age old Diagnosis treatmentnaive CNV secondary agerelated macular degeneration ( AMD ) study eye , BCVA score 78 19 letter inclusive , Patients structural foveal damage study eye , Patients confound severe oculare disease , Patients suspicion ( Polypoidal Choroidal Vasculapathy PCV ) study eye , Patients active suspect periocular infection either eye active intraocular inflammation either eye , Patients previous subfoveal laser photocoagulation study eye history vitrectomy surgery study eye , Patients prior treatment study eye , e.g. , Visudyne* , Avastin* , prior Ranibizumab treatment , Ozurdex* , external radiation therapy , transpupillary thermotherapy ( TTT ) , intravitreal injection , Patients know sensitivity Ranibizumab component formulation , Patients use investigational agent last 30 day , Concurrent participation clinical trial within 30 day prior enrollment , Patients receive systemic treatment antivascular endothelial growth factor ( VEGF ) therapy â‰¤ 60 day prior enrollment Patients physical mental disability prevent accurate vision testing , Patients physically unable tolerate intravenous fluorescein angiography , Pregnant breastfeed female patient , Any patient recent history new onset cardiac disease thromboembolic central nervous system ( CNS ) event ( within 12 month Baseline Visit ) , Patients condition , opinion Investigator , would require treatment would significantly impact treatment assessment study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Treat Extend</keyword>
	<keyword>wetAMD</keyword>
	<keyword>Age relate macular degeneration</keyword>
</DOC>